Jill Wechsler

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.


New Alzheimer’s Drug Heightens Debate Over FDA Accelerated Approval Process

FDA’s approval of Biogen’s treatment for Alzheimer’s disease has raised questions about the agency’s accelerated approval process.

Biden Budget “Wish List” Maps FDA and Health Care Priorities

The Biden administration supports a notable increase in funding for public health and research as a lead priority for the coming year.

Harmonized Lifecycle Management Policy Aims to Drive Drug Quality and Innovation

FDA recently published a final guidance for making post-approval manufacturing changes to drugs and biologics, the culmination of a long-running effort to facilitate improvements in medical product quality through the product life cycle.